ADMA Biologics (ADMA) Hit With Federal Securities Lawsuit Over Revenue Inflation Allegations

With an upside imaginable of 121.45%, ADMA Biologics, Inc. (NASDAQ:ADMA) ranks among the stocks nether $20 that volition explode. The institution is navigating a crisp disagreement betwixt bullish expert sentiment and mounting ineligible scrutiny tied to allegations from earlier this year.

On June 10, 2026, Raymond James expert Ryan Deschner resumed sum of ADMA Biologics, Inc. (NASDAQ:ADMA) with an "Outperform" standing and a $21 terms target. Deschner told investors that ADMA has transformed into a profitable, high-growth institution implicit the past fewer years, and said its maturation is insulated from "Most Favored Nation" policies, tariffs, and Medicare pricing negotiations, fixed the quality of its plasma-derived programs and its U.S.-based manufacturing and sales.

That bullish telephone came conscionable days before TheFly reported connected June 15, 2026, that ADMA Biologics, Inc. (NASDAQ:ADMA) is facing a national securities lawsuit.

The suit alleges ADMA Biologics, Inc. (NASDAQ:ADMA) inflated its flagship product's revenues done transmission stuffing and concealed a organisation narration tied to an entity allegedly controlled by a elder executive. The complaint, filed successful the U.S. District Court for the District of New Jersey, claims ADMA and definite elder executives made materially mendacious and misleading statements astir gross growth, interior controls, and related-party transactions.

The allegations followed a Culper Research short-seller study published connected March 24, 2026. ADMA Biologics, Inc. (NASDAQ:ADMA) shares fell astir 16.6% that day, different 15% connected March 25, and an further 13.9% connected March 26, closing astatine $8.29, down from astir $13.59 earlier the report. Cantor Fitzgerald said the company's effect lacked circumstantial feedback addressing the report's claims.

ADMA Biologics, Inc. (NASDAQ:ADMA) is simply a biopharmaceutical institution that manufactures, markets, and develops specialty plasma-derived biologics. It conducts operations done 2 concern segments: ADMA BioManufacturing and Plasma Collection Center.

While we admit the imaginable of ADMA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.